Component
Human taxane-trial baseline serum carnitine status
Human taxane-trial baseline serum carnitine status
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_access
- Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
- experimental_model
- Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile.
- interpretation_status
- Source-derived curation with stated access limits; ungraded, not independent replication.
- limitations
- Recorded association/adjustment only. Neither proves all patients were replete nor tests every clinically deficient population.
- nutrient_topic
- Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
- plain_language
- Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial.
- primary_references
- Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. | https://pubmed.ncbi.nlm.nih.gov/23733756/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3699727/ | https://doi.org/10.1200/jco.2012.44.8738
- source_locator
- Reviewed reference taxane-low-quarter; The baseline definition was not a validated clinical deficiency threshold and did not isolate plasma ALCAR as the causal factor. Adjusted week-24 FACT-NTX difference −2.3 points, P=0.007; baseline status was not associated with neuropathy in either arm.
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 551–557
AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile. · Recorded from source · Recorded from source
### taxane-low-quarter Adjusting for baseline carnitine status did not remove the adverse ALCAR effect in the taxane trial. The baseline definition was not a validated clinical deficiency threshold and did not isolate plasma ALCAR as the causal factor. Adjusted week-24 FACT-NTX difference −2.3 points, P=0.007; baseline status was not associated with neuropathy in either arm. Model and exposure: Women receiving adjuvant paclitaxel/docetaxel; ALCAR 3 g/day for 24 weeks. Trial-defined deficiency was the lowest carnitine quartile. Limitations: Recorded association/adjustment only. Neither proves all patients were replete nor tests every clinically deficient population. Reference: Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. | 2013 | https://pubmed.ncbi.nlm.nih.gov/23733756/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC3699727/ | https://doi.org/10.1200/jco.2012.44.8738 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.